Atara Biotherapeutics (ATRA) Operating Leases (2019 - 2026)

Atara Biotherapeutics (ATRA) has reported Operating Leases for 8 consecutive years, with $8.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 43.07% year-over-year to $8.8 million; the trailing twelve-month figure through Jun 2026 stood at $8.8 million (down 43.07% YoY), and the FY2025 full-year result was $9.3 million, down 68.75% from the prior year.
• Operating Leases slipped to $8.8 million in Q2 2026 per ATRA's latest filing, from $9.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $64.0 million in Q2 2022 and bottomed at $8.8 million in Q2 2026.
• Historically, Operating Leases has averaged $35.1 million across 5 years, with a median of $37.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 425.36% in 2022, then plunged 68.75% in 2025.
• Over 5 years, Operating Leases stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then slumped by 34.53% to $29.9 million in 2024, then slumped by 68.75% to $9.3 million in 2025, then slipped by 6.04% to $8.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $8.8 million, $9.1 million, and $9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.